Literature DB >> 34484985

Association between C-Maf-inducing protein gene rs2287112 polymorphism and schizophrenia.

Yingli Fu1,2, Xiaojun Ren3, Wei Bai4, Qiong Yu2, Yaoyao Sun2, Yaqin Yu2, Na Zhou5.   

Abstract

BACKGROUND: Schizophrenia is a severely multifactorial neuropsychiatric disorder, and the majority of cases are due to genetic variations. In this study, we evaluated the genetic association between the C-Maf-inducing protein (CMIP) gene and schizophrenia in the Han Chinese population.
METHODS: In this case-control study, 761 schizophrenia patients and 775 healthy controls were recruited. Tag single-nucleotide polymorphisms (SNPs; rs12925980, rs2287112, rs3751859 and rs77700579) from the CMIP gene were genotyped via matrix-assisted laser desorption/ionization time of flight mass spectrometry. We used logistic regression to estimate the associations between the genotypes/alleles of each SNP and schizophrenia in males and females, respectively. The in-depth link between CMIP and schizophrenia was explored through linkage disequilibrium (LD) and further haplotype analyses. False discovery rate correction was utilized to control for Type I errors caused by multiple comparisons.
RESULTS: There was a significant difference in rs287112 allele frequencies between female schizophrenia patients and healthy controls after adjusting for multiple comparisons (χ2 = 12.296, P adj = 0.008). Females carrying minor allele G had 4.445 times higher risk of schizophrenia compared with people who carried the T allele (OR = 4.445, 95% CI [1.788-11.046]). Linkage-disequilibrium was not observed in the subjects, and people with haplotype TTGT of rs12925980-rs2287112-rs3751859-rs77700579 had a lower risk of schizophrenia (OR = 0.42, 95% CI [0.19-0.94]) when compared with CTGA haplotypes. However, the association did not survive false discovery rate correction.
CONCLUSION: This study identified a potential CMIP variant that may confer schizophrenia risk in the female Han Chinese population.
© 2021 Fu et al.

Entities:  

Keywords:  C-Maf-inducing protein; CMIP; Gene polymorphism; Haplotype analysis; Schizophrenia

Year:  2021        PMID: 34484985      PMCID: PMC8381876          DOI: 10.7717/peerj.11907

Source DB:  PubMed          Journal:  PeerJ        ISSN: 2167-8359            Impact factor:   2.984


Introduction

Schizophrenia (SCZ) is a severely multifactorial neuropsychiatric disorder that affects almost 1% of adults around the world. A recent study found that the lifetime prevalence of SCZ patients in China was 0.6% (Huang et al., 2019). SCZ has devastating impacts on patients’ and their families’ quality of life. It also has an enormous financial cost. SCZ is a prototypical multifactorial disorder caused by both genetic and environmental factors. Genetic factors play a major role in SCZ etiology (Owen, Sawa & Mortensen, 2016) and genetic variations in chromosome 16 are associated with a variety of neuropsychiatric disorders. Some rare, common, and copy number variants on chromosome 16p have been found to be associated with SCZ (Chang et al., 2017; Giaroli et al., 2014). Regions on chromosome 16q, highly specific to a single psychometric measure, are also associated with neuropsychiatric disorders. Previous studies found that regions on chromosome 16q may increase susceptibility to SCZ (Lewis et al., 2003), bipolar disorder (Lewis et al., 2003), and autism (Wassink et al., 2008). Furthermore, large-scale genome-wide association studies (GWAS) conducted by Bigdeli et al. (2020) and Pardiñas et al. (2018) respectively showed two (rs34753377 and rs6500603) and three (rs17465671, rs12447542 and rs2161711) single-nucleotide polymorphisms (SNPs), located on chromosome 16 that were associated with SCZ. C-Maf-inducing protein (CMIP) is an important gene located on 16q23 that is mainly expressed in human brains, encodes an 86-kDa protein 7-9, and plays a role in the T-cell signaling pathway (Liu et al., 2015). CMIP contributes to several biological pathways and is involved in various diseases such as glioma, gastric cancer, kidney disease, and dyslipidemia (Li et al., 2019; Mo et al., 2018; Wang & Wu, 2017; Zhang et al., 2017), as well as major depressive disorder, syndromic autism spectrum disorders, and specific language impairments (Eicher & Gruen, 2015; Gedik, 2017; Luo et al., 2017; Wang et al., 2015). However, no studies have documented the relationship between CMIP and SCZ. Based on chromosome 16’s biological function and previous studies on CMIP, we hypothesized that CMIP may have a relationship with SCZ. Additionally, gender-specific associations between gene SNPs (i.e., RELN, GABRB3 and MTHFR) and SCZ have been found in several other studies (Sozuguzel & Sazci, 2019; Wan et al., 2019; Liu et al., 2018). We conducted a genetic association study stratified by gender to examine the association between tag SNPs of the CMIP gene and SCZ in the Han Chinese population.

Materials & Methods

Study sample

A total of 761 SCZ patients and 775 healthy controls without any personal or family history of mental illness were enrolled in this study. More details of the data collection are described in a previous paper (Fu et al., 2020). All subjects were recruited after providing written informed consent. The study was performed in accordance with the protocols approved by the Ethics Committee of Jilin University, China (2014-05-01).

SNP analysis

We searched for tag SNPs of CMIP using the Haploview program (http://hapmap.ncbi.nlm.nih.gov/). We found a total of 235 tag SNPs and selected four tag SNPs (rs12925980, rs2287112, rs3751859 and rs77700579) that were associated with some neuropsychiatric disorders in order to determine the associations with SCZ. We searched for minor allele frequencies (MAF) for each SNP across 1,000 genomes. The four SNPs’ MAF threshold was set above 0.05 for the Chinese Han population (CHB). Genomic DNA was extracted from five mL of peripheral blood collected from each subject using a commercial DNA extraction kit (Kangwei Biotech Company, Beijing, China) according to the manufacturer’s instructions. SNP genotyping was performed using matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). The forward and reverse primers for these four SNP amplifications are listed in Table 1.
Table 1

Primers for polymerase chain reaction.

SNPPrimer sequence (5′–3′)
ForwardReverse
rs2287112ACGTTGGATGATCAGCAAGAGCCTCAAACCACGTTGGATGTGGTTGCTGGTCTGCTTTTC
rs77700579ACGTTGGATGAGGATAGTGAGCACTTACCCACGTTGGATGGACAATGACAGCACCACCTC
rs3751859ACGTTGGATGTTTCCACCAGTGCTCAGGGACGTTGGATGGTTCTCCAGGTTCAAATGTC
rs12925980ACGTTGGATGCCCTTCCCCCATTGATACTCACGTTGGATGCACTAACTTCTTCAGCCCTC

Statistical analysis

We compared the demographic variables and allele and genotype distributions between patients and controls using Pearson’s chi-square (χ) test and Student’s t-test. Multiple logistic regression was used to test the association between SCZ and alleles or genotypes. IBM SPSS (version 24.0) was used for the statistical analyses mentioned above and R software (version 3.2.3) was used for type I error correction using the false discovery rate (FDR) method. In both case and control groups, we used the goodness of fit χ test to test the Hardy–Weinberg equilibrium (HWE) by online software SNPStats (https://www.snpstats.net/snpstats/start.htm). Haploview 4.2 and SNPStats were then used for linkage disequilibrium (LD) and haplotype analysis. Finally, we used Quanto 1.2.4 software to calculate the statistical power for each SNP according to the MAF (rs12925980: 0.495, rs2287112: 0.175, rs3751859: 0.369 and rs77700579: 0.131). SCZ prevalence was presupposed to be 1% according to previous studies. All tests were two-sided and a Padj-value less than 0.05 was considered statistically significant.

Results

Demographic characteristics

The case group consisted of 761 SCZ patients (58.2% males, mean age = 34.61 ± 12.02 years) and the control group consisted of 775 healthy people (56.2% males, mean age = 34.74 ± 11.41 years). Cases and controls were matched by sex (χ = 0.681, P = 0.409) and age (t = 0.221, P = 0.825). All SNPs were in accordance with the HWE in the control group (Table 2).
Table 2

Test of HWE for case and control groups, all SNPs were in accordance with the HWE in the control group.

SNPCaseControl
H0He χ 2 P H0He χ 2 P
rs129259800.4830.4860.0260.8710.4880.4810.1860.666
rs37518590.4490.4410.2780.5980.4150.4351.7390.187
rs22871120.2120.2419.9750.0020.2280.2240.2980.585
rs777005790.1730.1730.0060.9370.1880.1910.1990.655

Note:

Ho, observed heterozygosity; He, expected heterozygosity.

Note: Ho, observed heterozygosity; He, expected heterozygosity.

Allele and genotype distribution

rs12925980, rs3751859 and rs77700579 had 98% detection rates and rs2287112 had a 96% detection rate. Table 3 shows the genotypic and allelic distribution of the four SNPs and the associations with SCZ in the overall sample. The genotypic distribution of rs2287112 was found to be significantly different between SCZ patients and healthy controls (P = 0.016), but the difference did not survive the FDR correction adjusted for the multiple comparison (Padj = 0.128). The similar distribution differences and associations were observed in the female group (Table 4). The allelic distribution was significantly different between females in the patient and control groups (Padj = 0.008). The GG genotype (OR = 4.445, 95% CI [1.227–16.105]) and G allele (OR = 4.445, 95% CI [1.788–11.046]) were risk factors for SCZ. The statistical power for rs2281112 was 0.949. More details are shown in Table 4. Tables 3 and 4 show the associations based on the recessive genetic model, and the results of other genetic models are listed in Tables S1–S4.
Table 3

Genotypic and allelic distributions of CMIP SNPs between SCZ patients and healthy controls in overall subjects.

SNPsGenotypeCase (n)Control (n) χ 2 P Padj OR (95 CI)
rs77700579AA+TA7337620.4750.4910.661
TT7100.710 [0.268–1.879]
Allele
T133813790.9880.320.661
A1421650.887 [0.700–1.124]
rs12925980TT+CT4794990.1930.660.661
CC2502730.953 [0.771–1.179]
Allele
T6066210.7740.3790.661
C8529320.937 [0.810–1.083]
rs3751859GG+GA6536850.3870.5340.661
AA75870.901 [0.650–1.250]
Allele
G97910500.2010.6540.661
A4774941.036 [0.889–1.207]
rs2287112TT+GT6827615.7540.016*0.1281
GG24112.419 [1.175–4.977]
Allele
T121413460.9140.3390.661
G1981981.109 [0.897–1.370]

Notes:

P < 0.05.

Padj represent P corrected by FDR.

OR, is abbreviation of Odds ratio; 95%CI is abbreviation of 95% confidence interval.

Table 4

Genotypic and allelic distributions of CMIP SNPs between SCZ patients and healthy controls stratified by different sex.

SNPsGenotypeFemaleMale
CaseControl χ 2 P P adj OR (95% CI)CaseControl χ 2 P P adj OR (95% CI)
rs3751859G/G–G/A267302 (89.1%)0.1110.7840.8241386 (89.6%)3830.270.5780.8451
(89.90%)(88.50%)
A/A30370.931 [0.559–1.551]45 (10.4%)500.886 [0.577–1.358]
(10.10%)(10.90%)(11.60%)
Aelle
G3934630.6860.4270.8241586(68%)58700.870.871
(66%)(68%)(68%)
A2012151.100 [0.869–1.391]2762790.983 [0.803–1.204]
(34%)(32%)(32%)(32%)
rs77700579A/A-T/A305337 (99.4%)0.2410.6590.8241428 (98.6%)4250.2950.6340.8451
(99.70%)(98.20%)
T/T121.718 [0.155–19.067]681.297 [0.445–3.784]
(0.30%)(0.60%)(1.40%)(1.80%)
Aelle
A5566130.0720.8240.82417827661.2170.2710.7331
(91%(90%)(90%)(88%)
T56651.044 [0.717–1.520]861001.187 [0.875–1.611]
(9%)(10%)(10%)(12%)
rs12925980C/C–C/T248 (82.9%)283 (83.5%)0.1940.6350.8241354 (82.3%)3670.0440.8470.871
(84.80%)
T/T51 (17.1%)56 (16.5%)1.083 [0.780–1.504]76 (17.7%)661.028 [0.777–1.360]
(15.20%)
Aelle
C4023480.1580.6910.8241726(87%)7600.4340.5150.8451
(59%)(58%)(88%)
T2762501.051 [0.840–1.314]112 (13%)1081.066 [0.879–1.292]
(41%)(42%)(12%)
rs2287112T/T–G/T276 (96.2%)335 (99.1%)6.1480.0230.0921406 (96.9%)426 (98.2%)1.4080.2751
G/G1134.445 [1.227–16.105]1380.7331.645 [0.674–4.019]
(3.80%)(0.90%)(3.10%)(1.80%)
Aelle
T55267012.2960.0010.008*18128522.8160.1220.7331
(96.20%)(99.10%)(96.90%)(98.20%)
G2264.445 [1.788–11.046]26161.645 [0.875–3.094]
(3.80%)(0.90%)(3.10%)(1.80%)

Notes:

Represent Padj< 0.05.

Padj represent P corrected by FDR.

OR is abbreviation of Odds ratio, 95% CI is abbreviation of 95% confidence interval.

Notes: P < 0.05. Padj represent P corrected by FDR. OR, is abbreviation of Odds ratio; 95%CI is abbreviation of 95% confidence interval. Notes: Represent Padj< 0.05. Padj represent P corrected by FDR. OR is abbreviation of Odds ratio, 95% CI is abbreviation of 95% confidence interval.

LD and haplotype analysis

As shown in Fig. 1, the R2 values were 19 across total subjects (A) and male (B) and female subjects (C). LD was not observed across these SNPs according to the criteria (R2 > 0.8). The four SNPs’ position relationship in CMIP according to the National Center for Biotechnology Information (NCBI, https://www.ncbi.nlm.nih.gov/) gene structure are shown in Fig. 1D. We conducted haplotype association analysis with SCZ across all participants because the LD analysis results were similar between the male and female groups. The haplotype analysis results (Table 4) indicated that the haplotype made of all four SNPs (rs12925980–rs2287112–rs3751859–rs77700579) had a significantly different distribution between SCZ patients and healthy controls (Padj = 0.018). Furthermore, we estimated nine common haplotypes with a frequency >1% in detail. The results showed that the haplotype TTGT was significantly associated with SCZ (OR = 0.42, 95% CI [0.19–0.94], P = 0.032), but when FDR-adjusted the P-value was greater than 0.05 (Table 5).
Figure 1

Linkage disequilibrium (LD) of four SNPs within CMIP in different subjects and the location of SNPs on CMIP gene structure.

R2 values were used to estimate the LD between pairwise SNPs. (A) LD of total subjects. (B) LD of male. (C) LD of female. (D) Location of four SNPs on CMIP gene.

Table 5

Association between rs12925980–rs2287112–rs3751859–rs77700579 haplotype and schizophrenia.

rs12925980–rs2287711–FrequencyOR (95%CI) P P adj
rs3751859–rs77700579TotalControlCase
CTGA0.34260.35480.3291
CTAA0.17820.17580.1791.07 [0.83–1.38]0.6200.620
TTGA0.16810.1630.1731.11 [0.85–1.44]0.4400.620
TGGA0.09450.09080.0991.10 [0.80–1.51]0.5500.620
TTAA0.0820.07690.091.26 [0.90–1.74]0.1700.453
CTGT0.04020.03570.0471.33 [0.82–2.17]0.2500.500
TGAA0.02790.03090.0250.83 [0.46–1.51]0.5400.620
CTAT0.02490.03070.0190.60 [0.30–1.22]0.1600.453
TTGT0.02340.03170.0130.42 [0.19–0.94]0.032*0.272

Notes:

P < 0.05.

OR is abbreviation of Odds ratio, 95% CI is abbreviation of 95% confidence interval.

Linkage disequilibrium (LD) of four SNPs within CMIP in different subjects and the location of SNPs on CMIP gene structure.

R2 values were used to estimate the LD between pairwise SNPs. (A) LD of total subjects. (B) LD of male. (C) LD of female. (D) Location of four SNPs on CMIP gene. Notes: P < 0.05. OR is abbreviation of Odds ratio, 95% CI is abbreviation of 95% confidence interval.

Discussion

Many studies have investigated the association between the CMIP gene and diseases such as mental neuropsychiatric disorder (Eicher & Gruen, 2015; Luo et al., 2017; Wang et al., 2015), cancer (Juan et al., 2019), and metabolic disease (Cao, Wang & Wu, 2018; Mo et al., 2018). In this study, we included 1,536 participants to study the association between four tag SNPs (rs12925980, rs22287112, rs3751859 and rs77700579) of the CMIP gene and SCZ. To the best of our knowledge, our study is the first of its kind to explore the correlation between CMIP and SCZ in the northeast CHB. We found that one loci (rs2287112) was associated with SCZ in females, indicating that CMIP was a potential risk genetic variant for SCZ. A large scale GWAS study conducted by Gedik (2017) found that the SNP rs77700579 in CMIP was associated with major depressive disorder (MDD), supporting the conclusion that CMIP was a potential candidate gene for neuropsychiatric disorders. Several studies have detected sex-distinct gene polymorphisms with SCZ, including LTA, TNFA, IFNGR2 and PLA2G12A (Inoubli et al., 2018; Jemli et al., 2017; Yang et al., 2016). Yu et al. (2013) found eight genes with differential expression in female and male SCZ patients. Our research group also found a sex-specific SNP of gene RELN with SCZ in a previous study (Bai et al., 2019). Considering that SCZ’s sex-specific molecular phenotype has been observed in previous studies, we first explored the association between CMIP and SCZ in all samples and then separately tested the association for the male and female subgroups. We found that the SNP rs2287112 was significantly associated with SCZ in the whole group and female subgroup with a statistically significant value of 0.05. However, in the whole group the P value did not withstand FDR correction. The association between rs2287112 and SCZ only existed after P value correction in the female group. The association was not observed in the male group, providing more evidence that the molecular phenotype in SCZ is sex-specific. It should be noted that rs2287112 was not in HWE in the SCZ group, which suggested population stratification. The population structure evaluation showed no stratification and the control group conformed to HWE, ruling out the possibility of population admixture. The deviation from HWE may have been caused by the association with the disease that exerted a strong selection on the genome (Li et al., 2011). Additionally, we carried out haplotype analysis to determine the association between the haplotype and SCZ and whether the combination of specific alleles could affect SCZ susceptibility. The TTGT haplotype (rs12925980–rs2287112–rs3751859–rs77700579) correlated with a lower risk of SCZ in our study population, but the association did not survive FDR correction. Similarly, the haplotype consisting of rs12929303–rs2287112–rs12925980 in CMIP was associated with developmental dyslexia in a Chinese population (Wang et al., 2015), suggesting that the haplotype including rs22287112 may contribute to disease susceptibility. The haplotype analysis further supported that rs2287112 allele G correlated with an increased SCZ risk. Since this was a cross-sectional study, several limitations should be mentioned. First, this study was limited to interpreting the causal relationship between genetic risk factors and SCZ. Second, we only analyzed four SNPs in this study and may have missed some other loci associated with SCZ. Additionally, owing to the failure of demographic characteristic and in-depth clinical trait collection, we were not able to analyze the association of these SNPs with different SCZ clinical features. We were also limited to interaction analysis between genes and environment. Further studies that incorporate a large-scale sample size with more demographic characteristic information are warranted to further substantiate the association between CMIP gene polymorphism and SCZ susceptibility.

Conclusion

This study presented evidence that a CMIP variant is associated with SCZ susceptibility in northeast Han Chinese women. Considering the limitations of our work, additional functional genomics studies are required to further explain the role of SCZ-associated CMIP variants.

Raw data of this study.

Sex: 1 = male, 2 = female; Group: 1 = case, 0 = control Click here for additional data file. Click here for additional data file. Click here for additional data file. Click here for additional data file. Click here for additional data file. Click here for additional data file.
  27 in total

1.  Sex-specific effects of methylenetetrahydrofolate reductase polymorphisms on schizophrenia with methylation changes.

Authors:  Lin Wan; Guofu Zhang; Min Liu; Chuanyue Wang; Yuhong Li; Rena Li
Journal:  Compr Psychiatry       Date:  2019-08-19       Impact factor: 3.735

2.  Female gender specific association of the Reelin (RELN) gene rs7341475 variant with schizophrenia.

Authors:  Mavi Deniz Sozuguzel; Ali Sazci; Mustafa Yildiz
Journal:  Mol Biol Rep       Date:  2019-04-12       Impact factor: 2.316

3.  Induction of C-Mip by IL-17 Plays an Important Role in Adriamycin-Induced Podocyte Damage.

Authors:  Yanbo Liu; Lin Su; Qiuxia Lin; Ying Han; Peng You; Qingfeng Fan
Journal:  Cell Physiol Biochem       Date:  2015

4.  Association study of RELN polymorphisms with schizophrenia in Han Chinese population.

Authors:  Wenqiang Li; Xueqin Song; Hongxing Zhang; Yongfeng Yang; Chengdi Jiang; Bo Xiao; Wei Li; Ge Yang; Jingyuan Zhao; Weiyun Guo; Luxian Lv
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-04-23       Impact factor: 5.067

5.  IFNGR2 genetic polymorphism associated with sex-specific paranoid schizophrenia risk.

Authors:  Achraf Jemli; Oumaima Inoubli; Fatma Trifa; Anouar Mechri; Ferid Zaafrane; Lotfi Gaha; Besma Bel Hadj Jrad
Journal:  Nord J Psychiatry       Date:  2016-08-26       Impact factor: 2.202

6.  Posterior probability of linkage analysis of autism dataset identifies linkage to chromosome 16.

Authors:  Thomas H Wassink; Veronica J Vieland; Val C Sheffield; Christopher W Bartlett; Rhinda Goedken; Deborah Childress; Joseph Piven
Journal:  Psychiatr Genet       Date:  2008-04       Impact factor: 2.458

7.  The association of the CMIP rs16955379 polymorphism with dyslipidemia and the clinicopathological features of IgA nephropathy.

Authors:  Man-Qiu Mo; Ling Pan; Qing-Mei Lu; Qiu-Lin Li; Yun-Hua Liao
Journal:  Int J Clin Exp Pathol       Date:  2018-10-01

8.  Association between PLA2G12A Polymorphisms and Schizophrenia in a Han Chinese Population from Northeast China.

Authors:  Guang Yang; Hongqin Xu; Huiping Zhang; Qiong Yu; Yanhua Wu; Jieping Shi; Wenwang Rao; Yueyue You; Changgui Kou; Yaqin Yu
Journal:  PLoS One       Date:  2016-07-19       Impact factor: 3.240

9.  Opposite Genetic Effects of CMIP Polymorphisms on the Risk of Type 2 Diabetes and Obesity: A Family-Based Study in China.

Authors:  Yaying Cao; Tao Wang; Yiqun Wu; Juan Juan; Xueying Qin; Xun Tang; Tao Wu; Yonghua Hu
Journal:  Int J Mol Sci       Date:  2018-03-28       Impact factor: 5.923

10.  Association of the CACNA2D2 gene with schizophrenia in Chinese Han population.

Authors:  Yingli Fu; Na Zhou; Wei Bai; Yaoyao Sun; Xin Chen; Yueying Wang; Mingyuan Zhang; Changgui Kou; Yaqin Yu; Qiong Yu
Journal:  PeerJ       Date:  2020-02-05       Impact factor: 2.984

View more
  1 in total

1.  Associations of cognitive impairment in patients with schizophrenia with genetic features and with schizophrenia-related structural and functional brain changes.

Authors:  Chuanjun Zhuo; Hongjun Tian; Jiayue Chen; Qianchen Li; Lei Yang; Qiuyu Zhang; Guangdong Chen; Langlang Cheng; Chunhua Zhou; Xueqin Song
Journal:  Front Genet       Date:  2022-08-19       Impact factor: 4.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.